

Influence of rapid eye movement sleep on all-cause mortality: a community-based cohort study

Jingjing Zhang^{1,*}, Xuting Jin^{1,*}, Ruohan Li¹, Ya Gao¹, Jiamei Li¹, Gang Wang¹

¹Department of Critical Care Medicine, the Second Affiliated Hospital of Xi'an Jiaotong University, 710004 Xi'an, China

* Equal contribution

Correspondence to: Gang Wang; email: gang_wang@xjtu.edu.cn

Keywords: polysomnography, rapid eye movement sleep, all-cause mortality, community

Received: October 25, 2018

Accepted: March 6, 2019

Published: March 13, 2019

Copyright: Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Introduction: Although the proportion and duration of rapid eye movement (REM) sleep are correlated with neurological and cardiovascular diseases, whether REM sleep is associated with all-cause mortality in community-based populations remains unknown.

Methods: A prospective study was performed within the Sleep Heart Health Study (SHHS, Registration NO. NCT00005275). Total sleep time, sleep efficiency, and REM sleep were measured using polysomnography. Cox proportional hazards regression models were used to estimate the association of the REM sleep with all-cause mortality.

Results: Over a mean follow-up period of 11.0 ± 3.1 y, 1234 individuals (21.9%) died. In the entire population, reduced REM sleep was significantly associated with increasing all-cause mortality. After adjustment for age, sex, race, body mass index, smoking status, total cholesterol, triglycerides, high-density lipoprotein, history of diabetes and hypertension, and the apnea-hypopnea index, the duration and proportion of REM sleep were found to be significantly associated with all-cause mortality when the lowest and the highest REM quartile groups were compared (hazard ratio, 95% confidence interval: 1.727, 1.434-2.079; 1.545, 1.298-1.839; respectively).

Conclusion: The proportion and duration of REM sleep are negatively associated with all-cause mortality. This finding emphasizes the importance of personalized sleep management in community-based populations.

INTRODUCTION

The sleep process can be divided into two predominant phases, non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. The former consists of three stages (N1, N2, N3) and constitutes 75% to 80% of the total sleep [1] while the latter [2] accounts for approximately 20% to 25% of the total sleep. The REM sleep is characterized by a low-voltage, high-frequency pattern in the beta or theta range on an electroencephalograph (EEG), as well as by muscle-tone attenuation and REM [1]. Resembling wakeful-

ness, REM sleep is a highly active mental state associated with dreaming, suspended thermoregulation, and autonomic irregularities [3]. Further, REM sleep plays a profound role in the early development of sensory systems (i.e., visual, auditory, etc.) [4], as well as learning and memory functions by selectively maintaining the newly formed synapses [5].

Over the past decade, evidences for an association between REM sleep and neurological and cardiovascular diseases have been accumulated [6-7]. Moreover, prior investigations have shown that a smaller

proportion of REM sleep is associated with elevated sleep/wake blood pressure ratios [8], which may increase the risk for cardiovascular morbidity and mortality [9-10]. A longer REM stage has also been reported to hasten recovery following stroke [11]. Despite the accrual of knowledge on the effects of REM sleep, its influence on all-cause mortality remains unknown, especially in the community population. The present study, therefore investigated the association between REM sleep and all-cause mortality using data from the Sleep Heart Health Study (SHHS), a large community-based perspective cohort.

RESULTS

Individual selection and clinical characteristics

Of the 5804 participants, two had no outcomes and 162 had no baseline REM data, ultimately leaving an analytical sample size of 5640. Participants were divided into the deceased group (1234, 21.9%) and the alive group (4406, 77.1%) based on occurrence of death over a mean follow-up period of 11.0 ± 3.1 y (Figure 1). In the present study, the longest and shortest follow-up time durations were 15.8 years and 3.7 years, respectively. Most of the study population was Caucasian (84.8%). The average age, body mass index (BMI), and apnea-hypopnea index (AHI) of the study participants were 63.14 ± 11.22 years, 28.15 ± 5.07 kg/m², and 10.12 ± 13.41 , respectively, in the entire population. Compared to the participants in the alive group, those

in the deceased group were significantly more likely to be older (72.59 ± 9.31 vs. 60.39 ± 10.20 years) and men (53.9% vs. 46.0%) ($P < 0.001$ for both). In comparison to the alive group, the deceased group showed a significantly higher AHI (12.41 ± 15.33 vs. 9.53 ± 13.00 events/h), and prevalence of hypertension and diabetes mellitus; they also showed a greater decrease in total-sleep time (340.21 ± 67.28 vs. 361.40 ± 59.86), sleep efficiency (78.79 ± 11.31 vs. 82.45 ± 9.90), and amount and proportion of deep sleep ($P < 0.001$ for all) (Table 1).

Association between sleep structure and all-cause mortality

Table 2 shows the relationship between different stages of sleep and all-cause mortality. The proportions of the N1 and N2 stages were found to be positively associated with all-cause mortality in the entire population (hazard ratio [HR], 95% confidence interval [CI]: 1.045, 1.033-1.058; 1.010, 1.005-1.015; respectively). However, the relationship between the proportion of the N3 stage and all-cause mortality was non-significant. The duration of REM sleep was found to be negatively associated with all-cause mortality (HR, 95% CI: 0.987, 0.985-0.989); this association was significant after adjustments for age, gender, and race in Model 1 (HR, 95% CI: 0.990, 0.988-0.992). Though the adjustments for BMI, smoking status, total cholesterol, triglycerides, high-density lipoprotein, history of diabetes, history of hypertension, and AHI in Model 2




Figure 1. Flow chart of participant selection. A total of 5640 individuals were included in the analysis.

weakened the relationship between REM-sleep duration and all-cause mortality, the correlation remained statistically significant (HR, 95% CI: 0.992, 0.989-0.994). Similarly, the proportion of REM sleep was also

negatively associated with all-cause mortality for the entire population (HR, 95% CI: 0.957, 0.948-0.965). It remained statistically significant even after adjustment for all variables (HR, 95% CI: 0.972, 0.963-0.981).

Table 1. Demographic and clinical characteristics at baseline.

	Entire population	Deceased	Alive	P value
Subject, n	5640	1234	4406	
Age, yr	63.14±11.22	72.59±9.31	60.39±10.20	<0.001
Male, n (%)	2691 (47.7)	665 (53.9)	2026 (46.0)	<0.001
Race, n (%)				<0.001
White	4785 (84.8)	1083 (87.8)	3702 (84.0)	
Black	478 (8.5)	123 (10.0)	355 (8.1)	
Other	377 (6.7)	28 (2.3)	349 (7.9)	
Smoking status, n (%)				<0.001
Never	2649 (47.3)	519 (42.2)	2130 (48.7)	
Current	537 (9.6)	107 (8.7)	430 (9.8)	
Former	2414 (43.1)	604 (49.1)	1810 (41.4)	
BMI, kg/m²	28.15±5.07	27.63±4.98	28.30±5.09	0.760
AHI, events/h	10.12±13.41	12.41±15.33	9.53±13.00	<0.001
Hypertension, n (%)	2390 (42.4)	750 (60.8)	1640 (37.2)	<0.001
Diabetes, n (%)	384 (7.1)	168 (14.0)	216 (5.2)	<0.001
TC, mg/dL	207.48±38.42	205.93±41.60	207.92±37.48	0.009
HDL, mg/dL	50.63±15.72	50.47±15.57	50.67±15.77	0.643
Triglycerides, mg/dL	150.26±101.76	154.97±106.76	148.97±100.32	0.677
Sleep time (min)	356.72±62.20	340.21±67.28	361.40±59.86	<0.001
sleep efficiency (%)	81.65±10.33	78.79±11.31	82.45±9.90	<0.001
timest1p (%)	5.44±3.95	6.09±4.63	5.26±3.72	<0.001
timest2p (%)	56.54±11.72	57.68±12.86	56.22±11.36	<0.001
timest3p (%)	18.21±11.87	18.00±13.15	18.28±11.50	<0.001
REMP (%)	19.80±6.27	18.23±6.71	20.24±6.07	<0.001
REM (min)	72.36±27.49	63.53±26.98	74.84±27.13	0.932
Deep sleep (min)	137.93±53.53	125.22±55.22	141.49±52.50	0.037
Deep sleep (%)	38.02±12.78	36.23±14.11	38.52±12.34	<0.001
ai_rem (events/h)	15.45±10.95	14.72±11.32	15.66±10.83	0.127
sao2 rem (%)	94.33±2.63	93.49±2.92	94.57±2.49	<0.001
Follow-up time (d)	4029.47±1138.75	2586.57±1219.32	4433.59±705.19	<0.001

BMI, body mass index; AHI, apnea-hypopnea index; TC, total cholesterol; HDL, high-density lipoprotein; REM, minutes spent in rapid eye movement sleep; REM-P, percent of sleep time in REM sleep; timest1p, percent of sleep time in stage 1; timest2p, percent of sleep time in stage 2; timest3p, percent of sleep time in stage 3; ai_rem, REM Arousal Index, total arousals in REM sleep per hours of REM sleep; sao2_rem, average SaO2 in REM sleep.

Table 2. Hazard ratio (95% CI) for the association between sleep architecture and all-cause mortality.

	Univariate Model	Multivariate Model 1	Multivariate Model 2
Sleep time (min)	0.995(0.994-0.996)	0.997(0.996-0.998)	0.998(0.997-0.999)
Sleep efficiency (%)	0.973(0.968-0.979)	0.983(0.976-0.989)	0.984(0.977-0.991)
timest1p (%)	1.045(1.033-1.058)	1.027(1.014-1.040)	1.019(1.005-1.033)
timest2p (%)	1.010(1.005-1.015)	1.005(1.000-1.010)	1.003(0.997-1.008)
times3p (%)	0.997(0.992-1.002)	1.002(0.997-1.007)	1.003(0.998-1.009)
REMP (%)	0.957(0.948-0.965)	0.965(0.956-0.974)	0.972(0.963-0.981)
REM (min)	0.987(0.985-0.989)	0.990(0.988-0.992)	0.992(0.989-0.994)
Deep sleep (min)	0.995(0.993-0.996)	0.996(0.995-0.998)	0.998(0.996-0.999)
Deep sleep (%)	0.987(0.982-0.991)	0.992(0.988-0.997)	0.995(0.990-1.000)
ai_rem (events/h)	0.992(0.986-0.997)	0.989(0.984-0.995)	0.985(0.979-0.992)
sao2 rem (%)	0.928(0.919-0.938)	0.945(0.934-0.957)	0.940(0.925-0.955)

Model 1: adjusted for age (category), gender, race; Model 2: Model 1 plus body mass index, smoking status, total cholesterol, triglycerides, high-density lipoprotein, history of diabetes, and history of hypertension, apnea-hypopnea index.

REM, minutes spent in rapid eye movement sleep; REMp, percent of sleep time in REM sleep; timest1p, percent of sleep time in stage 1; timest2p, percent of sleep time in stage 2; timest3p, percent of sleep time in stage 3; ai_rem, REM Arousal Index, total arousals in REM sleep per hours of REM sleep; sao2_rem, average SaO2 in REM sleep.

Association between REM sleep and all-cause mortality

To further explore the relationship between REM sleep and all-cause mortality, we divided the population into quartiles on the basis of the amount of REM sleep. Using the highest quartile as a reference, the HR of all-cause mortality in the quartile with the lowest REM-sleep duration was 2.474 (95% CI, 2.087-2.932). However, after adjustment for age, sex, and race in Model 1, the influence of REM sleep duration on all-cause mortality was slightly diminished (HR, 95% CI: 1.933, 1.630-2.294). More adjustment with BMI, AHI, smoking status, blood lipid spectrum, and histories of diabetes and hypertension in Model 2, led to a further decrease in the intensity of the association, which nevertheless remained statistically significant (HR, 95% CI: 1.727, 1.434–2.079). In addition, we also found a linear association between REM sleep-duration quartiles and all-cause mortality (P for trend < 0.001 in both Model 1 and Model 2). Similarly, with the highest quartile as a reference, the association between the lowest proportion of REM sleep and all-cause mortality

was significant after adjustment for all variables in the regression model (HR, 95% CI: 1.545, 1.298-1.839), and the linear association also existed between REM-sleep proportion quartiles and all-cause mortality (P for trend < 0.001) (Table 3).

DISCUSSION

Our study identified an association between the duration and proportion of REM sleep and all-cause mortality. Moreover, we found that all-cause mortality decreases with an increase in the duration and proportion of REM sleep. This association was found to be independent of age, sex, race, BMI, AHI, smoking status, blood lipid spectrum, history of diabetes and hypertension. In addition, we found a positive correlation between all-cause mortality and the proportion of N1 and N2 stages (light sleep). However, our study did not identify a statistically significant association between the proportion of N3 stage and all-cause mortality, likely because the N3 stage alone has no obvious predictive value in the community population.

Table 3. Hazard ratio (95% CI) for the association between REM sleep quartiles and all-cause mortality.

	Quartiles of rapid eye movements				Overall Tendency
	Q1 (low)	Q2	Q3	Q4 (high)	
REM (min)					
Subjects, n	1438	1384	1434	1384	
Events, n (%)	449 (31.2)	321 (23.2)	275 (19.2)	189 (13.7)	
Univariate Model	2.474 (2.087–2.932)	1.774 (1.483–2.124)	1.451 (1.206–1.746)	1 (Ref)	0.748(0.711-0.788)
Model 1	1.933 (1.630–2.294)	1.440 (1.202–1.724)	1.248 (1.037–1.503)	1 (Ref)	0.805(0.764-0.848)
Model 2	1.727 (1.434–2.079)	1.384 (1.141–1.680)	1.202 (0.986–1.466)	1 (Ref)	0.835(0.789-0.884)
REMP (%)					
Subjects, n	1411	1407	1415	1407	
Events, n (%)	429 (30.4)	306 (21.7)	273 (19.3)	226 (16.1)	
Univariate Model	2.020 (1.720–2.373)	1.385 (1.166–1.644)	1.219 (1.022–1.453)	1 (Ref)	0.793(0.753-0.884)
Model 1	1.715 (1.460–2.016)	1.256 (1.057–1.491)	1.150 (0.964–1.372)	1 (Ref)	0.836(0.759-0.880)
Model 2	1.545 (1.298–1.839)	1.257 (1.046–1.510)	1.129 (0.934–1.364)	1 (Ref)	0.865(0.819-0.914)

Model 1: adjusted for age (category), gender, race; Model 2: Model 1 plus body mass index, smoking status, total cholesterol, triglycerides, high-density lipoprotein, history of diabetes, and history of hypertension, apnea-hypopnea index.

REM, minutes spent in rapid eye movement sleep; REMP, percent of sleep time in REM sleep.

Sleep is indispensable to not only the central nervous system but also to all the other physiological systems [1]. Previous studies have linked the quality of sleep with sleep architecture, which is composed of NREM sleep and REM sleep. The former can be further divided into three stages: N1, N2, and N3. The NREM sleep maintains cell homeostasis by reducing the number of synaptic connections to a basic level, which is necessary for normal physical and intellectual performance and behavior [12]. Along with the REM sleep, the N3 stage, defined as deep sleep, reflects the sleep quality [6]. Prior research has identified relationships between the REM-sleep and neurological and cardiovascular diseases, patients with cognitive impairment exhibit reduced REM sleep [13-14]; Pase et al. found that relatively shorter REM sleep is associated with a higher risk of developing dementia [15]. Giubilei et al. found that the number and duration of REM phases were significantly reduced in the acute phase of ischemic stroke as well as correlated with the severity of neurological deficits at prognosis [16]. Further, an observational study of 186 middle-aged African-American and Caucasian adults revealed that the greater sleep/wake ratios of blood pressure were correlated with a smaller proportion of REM sleep [8], which may increase the risk of cardiovascular morbidity and mortality [9-10]. However, to the best of our knowledge,

this study is the first to evaluate the association between the amount of REM sleep and all-cause mortality.

Recent investigations have suggested that the initiation and maintenance of REM sleep is due to certain brainstem structures [11, 17-18]. Glutamatergic neurons in the sublateralodorsal tegmental (SLD) nucleus function as REM-on neurons while GABAergic neurons situated in the pons function as REM-off neurons during NREM sleep [19-20]. Furthermore, another study found that REM sleep is triggered when the REM-off neurons are inactivated by the REM-on GABAergic neurons localized in the ventrolateral periaqueductal gray and the dorsal paragigantocellular nucleus [21]. The disinhibited ascending SLD REM-on neurons then induce cortical activation, while the descending ones initiate muscle atonia and sensory inhibition [22]. The triggering of REM sleep may be explained by the recruitment of neurons in the suprachiasmatic nucleus (SCN), which underlie the circadian clock critical for establishing the circadian rhythm in animals [23]. Moreover, multiple investigations have indicated the correlation between neuronal electrical activity originating in the SCN and the sleep stages [24-25].

Considering the association between SCN and sleep architecture, we speculate that aberrant SCN activity

may underlie the shortening of REM sleep. In addition to the disruptions of circadian rhythms concomitant with aging [26], research has shown that the amount of REM sleep is reduced by approximately 50% in late life [27-28]. Further, both the circadian rhythm and the length of REM sleep are affected by psychosocial stress and functioning of the hypothalamus-pituitary-adrenal (HPA) axis, a system important for the regulation of stress responses. Several studies have reported that dysregulation of the HPA axis leads to higher evening cortisol concentrations and shorter REM-sleep duration [27, 29]. Furthermore, multiple investigations have revealed that disruption of the circadian rhythm in critically ill patients in the intensive care unit may be explained by reduced REM sleep [30]. Decreased REM sleep may therefore indicate an aberrant circadian rhythm, and hence, a decreased SCN function. The disruptions to daily sleep/wake rhythms as well as many physiological and neuroendocrine cycles may ultimately account for a rise in the risk of all-cause mortality.

This study is subject to several limitations. First, the present study was mainly composed of middle-aged and older Caucasian adults, and therefore may not be generalized to all age and ethnic groups. Second, as the causes of death in the SHHS were not obtained, the relationship between REM sleep and specific fatal diseases should be explored by future analyses. Third, only the baseline measurement of REM sleep monitored by in-home polysomnography was available for the individuals in this dataset. In future, long-term REM sleep monitoring should be performed to clarify the association between REM sleep and all-cause mortality. Lastly, we did not further analyze the effect of REM sleep waveform on all-cause mortality due to pilot study. The microstructure of REM stage and detailed recordings of specific waveform across subjects by means of EEG are required for further investigation. Notwithstanding these limitations, the results presented here help to fill an important gap in the existing literature regarding the association between REM sleep and all-cause mortality.

In conclusion, increased sleep time and amount of REM sleep are associated with less all-cause mortality in the studied cohort of middle-aged and older adults. Our findings provide further evidence that the duration and proportion of REM sleep may serve as predictive factors for all-cause mortality. Investigation into the relationship between REM sleep and specific fatal diseases is therefore warranted. Further, as sleep architecture is regulated by circadian rhythm, we hypothesize that the extent of REM sleep may reflect the SCN functioning.

METHODS

Study design and participants

The SHHS (registration number, NCT00005275) is a community-based, multi-center, prospective cohort study designed to identify the cardiovascular outcomes of sleep-disordered breathing among individuals aged \geq 40 years. Of the 11145 people who were eligible for enrollment in the SHHS from 1995-1998, 5804 ultimately agreed and provided informed consent to complete the baseline interview and health examination. The heart-health outcomes including survival or decease were monitored until 2011. The protocol was approved by the Institutional Review Board of each participating institution: Boston University, Case Western Reserve University, Johns Hopkins University, Missouri Breaks Research Inc., New York University Medical Center, University of Arizona, University of California at Davis, University of Minnesota-Clinical and Translational Science Institute, and the University of Washington. The data were accessed on the basis of a signed agreement with the Brigham and Women's Hospital, Boston, MA, USA [31].

Polysomnography

Participants in the SHHS underwent an in-home EEG-based polysomnography performed with the Compumedics P-series portable monitor (Abbotsford, Victoria, Australia). Details regarding the polysomnographic equipment, hook-up procedures, scoring, quality assurance and control have been described elsewhere [32]. Sleep recordings were staged in epochs of 30 s and categorized as N1 (stage 1 sleep), N2 (stage 2 sleep), N3 (stage 3 sleep), REM (REM sleep), or W (awake); the first two stages constitute light sleep, while N3 and REM comprise deep sleep [33]. All other sleep parameters were calculated on the basis of these sleep stages. Total-sleep time was obtained by measuring the time spent across all sleep stages; sleep efficiency was obtained by comparing the time spent asleep relative to that spent in bed.

Assessment of mortality

When subjects could not be contacted for their scheduled follow-up, every attempt was made to determine whether or not they were deceased. All the known contacts for the subject were called to determine the subject's vital status. Moreover, both the local death registries and the National Death Index were searched for the subject's name or social security number. When a death was ascertained, the parent study obtained records from any hospitalization that occurred within one month of death, a copy of the death certificate, and,

if performed, an autopsy report. In addition, the subject's physician and his or her family member or other proxy who was with the subject when he or she passed away was interviewed to obtain details concerning the circumstances of the death.

Covariates

During the SHHS home visit, a study technician collected each participant's health history using a standardized questionnaire before polysomnogram monitoring was performed. Smoking status was classified as 'never' (if the participant reported smoking fewer than 20 packs of cigarettes during his or her lifetime), 'former', or 'current'. Participants' BMI and blood-lipid measurements were obtained using standardized protocols at the SHHS baseline examination. History of hypertension was identified based on the second and third blood pressure readings or if the participant was being treated with hypertension agents. History of diabetes mellitus was ascertained based on the report of a physician-administered diagnosis or on the reported use of insulin or oral hypoglycemic medication. The AHI was defined as the average number of apneas and hypopneas, each associated with a 4% decrease in oxygen saturation per hour of sleep [31].

Statistics analyses

Values represent the mean \pm standard deviation for continuous variables and percentages for categorical variables. Cox proportional hazards regression modelling was used to examine the association between REM sleep and all-cause mortality. Multivariate models were adjusted for the following factors: (i) age, gender and race in Model 1; (ii) age, gender, race, BMI, smoking status, total cholesterol, triglycerides, high-density lipoprotein, history of diabetes mellitus and history of hypertension and AHI in Model 2. P values of < 0.05 were considered to be statistically significant. All statistical analyses were performed with the SPSS software package version 22.0 (IBM Corp., Armonk, NY, USA).

ACKNOWLEDGEMENTS

We appreciate the Brigham and Women's Hospital for sharing the datasets of the SHHS. The SHHS acknowledges the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, the Cornell/Mt. Sinai Worksite and Hypertension Studies, the Strong Heart Study, the Tucson Epidemiologic Study of Airways Obstructive Diseases, and the Tucson Health and Environment Study for allowing their cohort members

to be part of the SHHS and for permitting the use of the data acquired by them. SHHS is particularly grateful to the members of these cohorts who agreed to participate in SHHS as well. SHHS further recognizes all of the investigators and staff who have contributed to its success. A list of SHHS investigators, staff, and their participating institutions is available on the SHHS website, <https://sleepdata.org/datasets/shhs>.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

FUNDING

This study was funded by the National Natural Science Foundation of China (81770057).

REFERENCES

1. Collop NA, Salas RE, Delayo M, Gamaldo C. Normal sleep and circadian processes. *Crit Care Clin*. 2008; 24:449–60. <https://doi.org/10.1016/j.ccc.2008.02.002>
2. Aserinsky E, Kleitman N. Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. *Science*. 1953; 118:273–74. <https://doi.org/10.1126/science.118.3062.273>
3. Kalia M. Neurobiology of sleep. *Metabolism*. 2006 (Suppl 2); 55:S2–6. <https://doi.org/10.1016/j.metabol.2006.07.005>
4. Graven SN, Browne JV. Sleep and Brain Development: The Critical Role of Sleep in Fetal and Early Neonatal Brain Development. *Newborn Infant Nurs Rev*. 2008; 8:173–79. <https://doi.org/10.1053/j.nainr.2008.10.008>
5. Li W, Ma L, Yang G, Gan WB. REM sleep selectively prunes and maintains new synapses in development and learning. *Nat Neurosci*. 2017; 20:427–37. <https://doi.org/10.1038/nn.4479>
6. Della Monica C, Johnsen S, Atzori G, Groeger JA, Dijk DJ. Rapid Eye Movement Sleep, Sleep Continuity and Slow Wave Sleep as Predictors of Cognition, Mood, and Subjective Sleep Quality in Healthy Men and Women, Aged 20-84 Years. *Front Psychiatry*. 2018; 9:255. <https://doi.org/10.3389/fpsy.2018.00255>
7. Ma C, Pavlova M, Liu Y, Liu Y, Huangfu C, Wu S, Gao X. Probable REM sleep behavior disorder and risk of stroke: A prospective study. *Neurology*. 2017; 88:1849–55. <https://doi.org/10.1212/WNL.0000000000003902>
8. Matthews KA, Kamarck TW, Hall M, Strollo PJ, Owens JF, Buysse DJ, Lee L, Reis SE. Blood pressure dipping and sleep disturbance in African-American

- and Caucasian men and women. *Am J Hypertens*. 2008; 21:826–31.
<https://doi.org/10.1038/ajh.2008.183>
9. Yan B, Sun L, Gao Y, Guo Q, Guo L, Wang X, Wang G. Blood pressure reverse dipping may associate with stable coronary artery disease in patients with essential hypertension: a cross-sectional study. *Sci Rep*. 2016; 6:25410.
<https://doi.org/10.1038/srep25410>
 10. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. *Hypertension*. 2005; 45:240–45.
<https://doi.org/10.1161/01.HYP.0000152079.04553.2c>
 11. Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. *J Biol Rhythms*. 2006; 21:482–93.
<https://doi.org/10.1177/0748730406294627>
 12. de Andrés I, Garzón M, Reinoso-Suárez F. Functional Anatomy of Non-REM Sleep. *Front Neurol*. 2011; 2:70. <https://doi.org/10.3389/fneur.2011.00070>
 13. Kundermann B, Thum A, Rocamora R, Haag A, Krieg JC, Hemmeter U. Comparison of polysomnographic variables and their relationship to cognitive impairment in patients with Alzheimer's disease and frontotemporal dementia. *J Psychiatr Res*. 2011; 45:1585–92.
<https://doi.org/10.1016/j.jpsychires.2011.07.008>
 14. Jiang B, Ding C, Yao G, Yao C, Zhang Y, Ge J, Qiu E, Elia M, Ferri R. Polysomnographic abnormalities in patients with vascular cognitive impairment-no dementia. *Sleep Med*. 2013; 14:1071–75.
<https://doi.org/10.1016/j.sleep.2013.07.003>
 15. Pase MP, Himali JJ, Grima NA, Beiser AS, Satizabal CL, Aparicio HJ, Thomas RJ, Gottlieb DJ, Auerbach SH, Seshadri S. Sleep architecture and the risk of incident dementia in the community. *Neurology*. 2017; 89:1244–50.
<https://doi.org/10.1212/WNL.0000000000004373>
 16. Giubilei F, Iannilli M, Vitale A, Pierallini A, Sacchetti ML, Antonini G, Fieschi C. Sleep patterns in acute ischemic stroke. *Acta Neurol Scand*. 1992; 86:567–71.
<https://doi.org/10.1111/j.1600-0404.1992.tb05488.x>
 17. García-García B, Reinoso-Suárez F, Rodrigo-Angulo ML. Hypothalamic hypocretinergic/orexinergic neurons projecting to the oral pontine rapid eye movement sleep inducing site in the cat. *Anat Rec (Hoboken)*. 2013; 296:815–21.
<https://doi.org/10.1002/ar.22690>
 18. Costa A, Castro-Zaballa S, Lagos P, Chase MH, Torterolo P. Distribution of MCH-containing fibers in the feline brainstem: relevance for REM sleep regulation. *Peptides*. 2018; 104:50–61.
<https://doi.org/10.1016/j.peptides.2018.04.009>
 19. Maloney KJ, Mainville L, Jones BE. c-Fos expression in GABAergic, serotonergic, and other neurons of the pontomedullary reticular formation and raphe after paradoxical sleep deprivation and recovery. *J Neurosci*. 2000; 20:4669–79.
<https://doi.org/10.1523/JNEUROSCI.20-12-04669.2000>
 20. Clément O, Sapin E, Bérod A, Fort P, Luppi PH. Evidence that neurons of the sublaterodorsal tegmental nucleus triggering paradoxical (REM) sleep are glutamatergic. *Sleep*. 2011; 34:419–23.
<https://doi.org/10.1093/sleep/34.4.419>
 21. Goutagny R, Luppi PH, Salvat D, Lapray D, Gervasoni D, Fort P. Role of the dorsal paragigantocellular reticular nucleus in paradoxical (rapid eye movement) sleep generation: a combined electrophysiological and anatomical study in the rat. *Neuroscience*. 2008; 152:849–57.
<https://doi.org/10.1016/j.neuroscience.2007.12.014>
 22. Luppi PH, Clement O, Sapin E, Peyron C, Gervasoni D, Léger L, Fort P. Brainstem mechanisms of paradoxical (REM) sleep generation. *Pflugers Arch*. 2012; 463:43–52. <https://doi.org/10.1007/s00424-011-1054-y>
 23. Kalsbeek A, Palm IF, La Fleur SE, Scheer FA, Perreault S, Ruiters M, Kreier F, Cailotto C, Buijs RM. SCN outputs and the hypothalamic balance of life. *J Biol Rhythms*. 2006; 21:458–69.
<https://doi.org/10.1177/0748730406293854>
 24. Lee ML, Swanson BE, de la Iglesia HO. Circadian timing of REM sleep is coupled to an oscillator within the dorsomedial suprachiasmatic nucleus. *Curr Biol*. 2009; 19:848–52.
<https://doi.org/10.1016/j.cub.2009.03.051>
 25. Deboer T, Vansteensel MJ, Détári L, Meijer JH. Sleep states alter activity of suprachiasmatic nucleus neurons. *Nat Neurosci*. 2003; 6:1086–90.
<https://doi.org/10.1038/nn1122>
 26. Colwell CS. Linking neural activity and molecular oscillations in the SCN. *Nat Rev Neurosci*. 2011; 12:553–69. <https://doi.org/10.1038/nrn3086>
 27. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. *JAMA*. 2000; 284:861–68.
<https://doi.org/10.1001/jama.284.7.861>
 28. Schwarz JF, Åkerstedt T, Lindberg E, Gruber G, Fischer

H, Theorell-Haglöw J. Age affects sleep micro-structure more than sleep macrostructure. *J Sleep Res.* 2017; 26:277–87.
<https://doi.org/10.1111/jsr.12478>

29. Gonnissen HK, Mazuy C, Rutters F, Martens EA, Adam TC, Westerterp-Plantenga MS. Sleep architecture when sleeping at an unusual circadian time and associations with insulin sensitivity. *PLoS One.* 2013; 8:e72877.
<https://doi.org/10.1371/journal.pone.0072877>
30. Boyko Y, Ording H, Jennum P. Sleep disturbances in critically ill patients in ICU: how much do we know? *Acta Anaesthesiol Scand.* 2012; 56:950–58.
<https://doi.org/10.1111/j.1399-6576.2012.02672.x>
31. Zhang J, Gong Z, Li R, Gao Y, Li Y, Li J, Yan B, Wang G. Influence of lung function and sleep-disordered breathing on stroke: a community-based study. *Eur J Neurol.* 2018; 25:1307–e112.
<https://doi.org/10.1111/ene.13722>
32. Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O'Connor GT, Rapoport DM, Redline S, Robbins J, Samet JM, Wahl PW. The Sleep Heart Health Study: design, rationale, and methods. *Sleep.* 1997; 20:1077–85.
33. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJ, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochweg B, Balas MC, van den Boogaard M, Bosma KJ, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. *Crit Care Med.* 2018; 46:e825–73.
<https://doi.org/10.1097/CCM.0000000000003299>